Cargando…
Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing
BACKGROUND: Nucleic acid amplification testing is a critical tool for addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Specimen pooling can increase throughput and conserve testing resources but requires validation to ensure that reduced sensitivity does not incr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543567/ https://www.ncbi.nlm.nih.gov/pubmed/33204756 http://dx.doi.org/10.1093/ofid/ofaa466 |
_version_ | 1783591702890545152 |
---|---|
author | Borillo, Gwynngelle A Kagan, Ron M Baumann, Russell E Fainstein, Boris M Umaru, Lamela Li, Hai-Rong Kaufman, Harvey W Clarke, Nigel J Marlowe, Elizabeth M |
author_facet | Borillo, Gwynngelle A Kagan, Ron M Baumann, Russell E Fainstein, Boris M Umaru, Lamela Li, Hai-Rong Kaufman, Harvey W Clarke, Nigel J Marlowe, Elizabeth M |
author_sort | Borillo, Gwynngelle A |
collection | PubMed |
description | BACKGROUND: Nucleic acid amplification testing is a critical tool for addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Specimen pooling can increase throughput and conserve testing resources but requires validation to ensure that reduced sensitivity does not increase the false-negative rate. We evaluated the performance of a real-time reverse transcription polymerase chain reaction (RT-PCR) test authorized by the US Food and Drug Administration (FDA) for emergency use for pooled testing of upper respiratory specimens. METHODS: Positive specimens were selected from 3 prevalence groups, 1%–3%, >3%–6%, and >6%–10%. Positive percent agreement (PPA) was assessed by pooling single-positive specimens with 3 negative specimens; performance was assessed using Passing-Bablok regression. Additionally, we assessed the distributions of RT-PCR cycle threshold (Ct) values for 3091 positive specimens. RESULTS: PPA was 100% for the 101 pooled specimens. There was a linear relationship between Ct values for pooled and single-tested specimens (r = 0.96–0.99; slope ≈ 1). The mean pooled Ct shifts at 40 cycles were 2.38 and 1.90, respectively, for the N1 and N3 targets. The median Cts for 3091 positive specimens were 25.9 (N1) and 24.7 (N3). The percentage of positive specimens with Cts between 40 and the shifted Ct was 1.42% (N1) and 0.0% (N3). CONCLUSIONS: Pooled and individual testing of specimens positive for SARS-CoV-2 demonstrated 100% agreement, which demonstrates the viability of pooled specimens for SARS-COV-2 testing using a dual-target RT-PCR system. Pooled specimen testing can help increase testing capacity for SARS-CoV-2 with a low risk of false-negative results. |
format | Online Article Text |
id | pubmed-7543567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75435672020-10-08 Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing Borillo, Gwynngelle A Kagan, Ron M Baumann, Russell E Fainstein, Boris M Umaru, Lamela Li, Hai-Rong Kaufman, Harvey W Clarke, Nigel J Marlowe, Elizabeth M Open Forum Infect Dis Major Articles BACKGROUND: Nucleic acid amplification testing is a critical tool for addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Specimen pooling can increase throughput and conserve testing resources but requires validation to ensure that reduced sensitivity does not increase the false-negative rate. We evaluated the performance of a real-time reverse transcription polymerase chain reaction (RT-PCR) test authorized by the US Food and Drug Administration (FDA) for emergency use for pooled testing of upper respiratory specimens. METHODS: Positive specimens were selected from 3 prevalence groups, 1%–3%, >3%–6%, and >6%–10%. Positive percent agreement (PPA) was assessed by pooling single-positive specimens with 3 negative specimens; performance was assessed using Passing-Bablok regression. Additionally, we assessed the distributions of RT-PCR cycle threshold (Ct) values for 3091 positive specimens. RESULTS: PPA was 100% for the 101 pooled specimens. There was a linear relationship between Ct values for pooled and single-tested specimens (r = 0.96–0.99; slope ≈ 1). The mean pooled Ct shifts at 40 cycles were 2.38 and 1.90, respectively, for the N1 and N3 targets. The median Cts for 3091 positive specimens were 25.9 (N1) and 24.7 (N3). The percentage of positive specimens with Cts between 40 and the shifted Ct was 1.42% (N1) and 0.0% (N3). CONCLUSIONS: Pooled and individual testing of specimens positive for SARS-CoV-2 demonstrated 100% agreement, which demonstrates the viability of pooled specimens for SARS-COV-2 testing using a dual-target RT-PCR system. Pooled specimen testing can help increase testing capacity for SARS-CoV-2 with a low risk of false-negative results. Oxford University Press 2020-09-29 /pmc/articles/PMC7543567/ /pubmed/33204756 http://dx.doi.org/10.1093/ofid/ofaa466 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles Borillo, Gwynngelle A Kagan, Ron M Baumann, Russell E Fainstein, Boris M Umaru, Lamela Li, Hai-Rong Kaufman, Harvey W Clarke, Nigel J Marlowe, Elizabeth M Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing |
title | Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing |
title_full | Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing |
title_fullStr | Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing |
title_full_unstemmed | Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing |
title_short | Pooling of Upper Respiratory Specimens Using a SARS-CoV-2 Real-time RT-PCR Assay Authorized for Emergency Use in Low-Prevalence Populations for High-Throughput Testing |
title_sort | pooling of upper respiratory specimens using a sars-cov-2 real-time rt-pcr assay authorized for emergency use in low-prevalence populations for high-throughput testing |
topic | Major Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543567/ https://www.ncbi.nlm.nih.gov/pubmed/33204756 http://dx.doi.org/10.1093/ofid/ofaa466 |
work_keys_str_mv | AT borillogwynngellea poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT kaganronm poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT baumannrusselle poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT fainsteinborism poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT umarulamela poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT lihairong poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT kaufmanharveyw poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT clarkenigelj poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting AT marloweelizabethm poolingofupperrespiratoryspecimensusingasarscov2realtimertpcrassayauthorizedforemergencyuseinlowprevalencepopulationsforhighthroughputtesting |